The present invention is directed to a pharmaceutical composition comprising the following compoundor a pharmaceutically acceptable salt thereof. The compound is a modulator of Nrf2 protein and binds at least one of the BTB domain, IVR domain and Kelch domain of Keap1 protein, activating or inhibiting Nrf2.